1410 related articles for article (PubMed ID: 19042080)
1. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
3. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
[TBL] [Abstract][Full Text] [Related]
4. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
6. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
7. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
9. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
12. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
17. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
